Navigation Links
The American Society for Microbiology honors Lawrence Corey

Lawrence Corey, M.D., president and director of Fred Hutchinson Cancer Research Center, has been honored with the 2012 Cubist-ICAAC Award. An internationally renowned expert in virology, immunology and vaccine development, Corey's research focuses on herpes viruses, HIV, and other viral infections, particularly those associated with cancer. "Corey's work was the first to demonstrate the safety of daily antiviral treatment for immunocompetent persons," explains his nominator, Wesley Van Voorhis of the University of Washington. "His studies led to the routine use of antivirals not only for HSV-2the field he has been the dominant figure in for three decadesbut also HCV, HBV, and HIV."

Corey earned his bachelor's and medical degrees from the University of Michigan, and completed infectious diseases training at the University of Washington School of Medicine. He joined the faculty of the University of Washington in 1978, where he remains today as a Professor of Laboratory Medicine and holder of the Lawrence Corey Endowed Chair in Medical Virology. He is also an infectious disease physician at Seattle Cancer Care Alliance, in addition to his duties as president and director of the Hutchinson Center.

Corey is the principal investigator of the Hutchinson Center-based HIV Vaccine Trials Network (HVTN), an international collaboration of scientists and institutions that combines clinical trials and laboratory-based studies to accelerate the development of HIV vaccines. Under Corey's leadership at the Hutchinson Center, the HVTN has become the model for global collaborative research, involving scientists on four continents and nine countries. "In this capacity, he has overseen the building of a clinical trials network infrastructure from only eight U.S. sites in 1998, to a program that has thirty clinical trial sites in fifteen countries on four continents," explains Anthony S. Fauci, NIAID, NIH. "This network is now at the forefront of clinical trials of HIV vaccine candidates."

Corey has been a pioneer in the development of antiviral therapy. In the early 1980s he worked with Nobel Prize-winning biochemist and pharmacologist Gertrude Elion to demonstrate that an antiviral that was selective and specific for a viral-specified enzyme could be safely and effectively administered to control a chronic viral infection (herpes simplex virus-2). These studies were directly responsible for the subsequent successful quest of the pharmaceutical and medical sciences communities to develop effective antiviral therapy for hepatitis B and HIV. In 1987 he directed the AIDS Clinical Trials Group, or ACTG, and under his leadership the use of the retroviral drug AZT to reduce maternal-fetal transmission of HIV and HAART (highly active retroviral therapy) were developed. His research group also was the first to identify an association between the virus that causes genital herpes (herpes simplex virus) and HIV. Through the ACTG he pioneered the integration of community members into clinical research activities.

"No one has contributed more to our understanding of herpes simplex virus pathogenesis and therapy than Corey," states Martin Hirsch, Harvard Medical School and Massachusetts General Hospital. "From early work demonstrating that certain treatments don't work, to landmark studies of topical, intravenous and oral acyclovir and its congeners, Corey has led the way. In his elegant studies of HSV latency, he may well open up new avenues to cure, rather than suppression. He has taught us more about the pathogenesis, immunology, and treatment of genital herpes than any other investigator in the field."

In the mid-1990s, Corey increasingly concentrated his scientific and leadership skills on the area of vaccine development, and in 1998 he worked with Fauci to develop a global clinical trials group to speed the development of HIV vaccines. In 2002, Corey recognized the need to further integrate research efforts in HIV vaccine development and spearheaded the development of the Global HIV Vaccine Enterprise, one of the few scientific programs overseen by leaders of the major industrialized countries. Fauci explains, "Corey is the only scientist in the country who had led two of our nation's major HIV clinical trials programsone in treatment and one in vaccine developmentand hence has a unique perspective on the treatment and prevention of HIV infection." Corey also conceived and led an international study that demonstrated that a daily dose of an antiviral drug cuts the transmission of the genital herpes virus by half. He currently is working to define how host immune cells control the herpes simplex virus and whether it will be possible to develop a vaccine to reduce infection reactivation.

In 2008, with funding from the Washington Life Sciences Discovery Fund, Corey founded the Hutchinson Center-based Washington Vaccine Alliance, or WAVA a virtual biotechnology coalition of nonprofit research institutions dedicated to developing novel vaccines for the prevention of human diseases ranging from typhoid to syphilis to salmonella poisoning. Corey's numerous honors and awards include election to the American Academy of Arts and Sciences and the Institute of Medicine. In addition, he received the Pan American Society's Clinical Virology Award and the Parran Award of the American Society for STD Research.

Contact: Garth Hogan
American Society for Microbiology

Related biology news :

1. American College of Rheumatology releases first classification criteria for polymyalagia rheumatica
2. Common North American frog identified as carrier of deadly amphibian disease
3. UC research tests new tool to guide reintroduction of the American chestnut
4. American Society of Plant Biologists honors early career women scientists
5. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
6. Professor known for work with hunter-gatherers elected to American Academy of Arts and Sciences
7. Elsevier selected as new publisher of the American Journal of Geriatric Psychiatry
8. New study published on fertility awareness among American university students
9. The American Society for Microbiology honors Ellen Jo Baron
10. Steve Fisher joins American Health IT LLC as VP of Operations
11. University of Tennessee anthropologists find American heads are getting larger
Post Your Comments:
(Date:10/27/2015)... Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ... so that they can be quantitatively analyzed with SMI,s ... Germany , October 28-29, 2015. SMI,s Automated Semantic ... eye tracking videos created with SMI,s Eye Tracking ...
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
(Date:10/23/2015)... BERLIN and GOLETA, California ... the HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce ... and eye tracking data captured during interactive real-world tasks ... plug and play integration of their established wearable solutions ... researchers to synchronize gaze behavior captured with SMI ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology: